Interferon alfa-2a treatment for chronic hepatitis C without cirrhosis and its effects on the incidence of hepatocellular carcinoma

Journal of Infection and Chemotherapy

Volumn 4, Issue 4, 1998, Pages 209-213

  Omagari, Katsuhisa ^a   Ikuno, Nobuhiro ^a   Imanishi, Takeo ^b   Hayashida, Kenji ^c   Inoue, Ken Ichiro ^d   Senju, Masahiro ^e   Mori, Norihiko ^f   Tanaka, Toshiro ^g   Nakamuta, Koji ^h   Oda, Hidetoshi ⁱ   Minamino, Atsushi ^j   Komatsu, Kohei ^k   Nomura, Yasuko ^l   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Koebaru Chuo Hospital   (Japan)

^c Miyaki gun   (Japan)

^d Shunkaikai Inoue Hospital   (Japan)

^e Senju Hospital   (Japan)

^f Hokusho Chuo Hospital   (Japan)

^g Imari Municipal Hospital   (Japan)

^h Shimabara Onsen Hospital   (Japan)

ⁱ Isahaya Insurance General Hospital   (Japan)

^j NTT Nagasaki Hospital   (Japan)

^k Ureshino Medical Center   (Japan)

^l NIPPON ROCHE RESEARCH CENTER   (Japan)

more..

Author keywords

Chronic hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Interferon alfa 2a; Long term follow up

Indexed keywords

EID: 0012155567     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02490168     Document Type: Article

References (19)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429-433.
3. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996;125:658-668.
4. Hoofnagle JH, Di Bisceglie AM.The treatment of chronic viral hepatitis. N Engl J Med 1997,336:347-356.
5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346: 1051-1055.
6. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
7. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kaminura T, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996,6:112-119.
8. Ishiyama N, Katayama K, Ishimi N, Takahashi S, Igarashi H, Nakajima H, et al. Quantitative detection of hepatitis C virus RNA by multicyclic RT-PCR. Int Hepatol Commun 1993; 1:72-79.
9. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
10. Sato A, Kato Y, Nakata K, Nakao K, Daikoku M, Ishii N, et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J Gastroenterol Hepatol 1996;11:944-948.
11. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79:688-694.
12. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-655.
13. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-749.
14. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1567.
15. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997,79:1494-1500.
16. Lai C-L, Lau JYN, Wu P-C, Ngan H, Chung H-T, Mitchell SJ, et al. Recombinant interferon-alpha in inoprable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-394.
17. Sata M, Ide T, Akiyoshi F, Fukuizumi K, Noguchi S, Shirachi M, et al. Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Kurume Med J 1997;44:171-177.
18. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15:225-236.
19. Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K, et al. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 1996;11:955-958.